Scarica l'app Stockscreener
240.01
0.94%
2.24
Dopo l'orario di chiusura:
240.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$237.77
Aprire:
$241.83
Volume 24 ore:
926.35K
Relative Volume:
1.07
Capitalizzazione di mercato:
$31.06B
Reddito:
$2.25B
Utile/perdita netta:
$-278.16M
Rapporto P/E:
-110.60
EPS:
-2.17
Flusso di cassa netto:
$-42.59M
1 W Prestazione:
+3.03%
1M Prestazione:
-0.72%
6M Prestazione:
-15.29%
1 anno Prestazione:
+61.62%
Intervallo 1D:
$234.18
$241.83
Intervallo di 1 settimana:
$205.87
$245.56
Portata 52W:
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
240.01 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.83 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.06 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
606.39 | 36.98B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
242.75 | 26.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires? - Insider Monkey
High Growth Tech Stocks In US With Potential For Expansion - simplywall.st
Morgan Stanley Lowers Alnylam (ALNY) Price Target Amid Earnings Preview | ALNY Stock News - GuruFocus
Cns Specific Antisense Oligonucleotide Market Is Booming - openPR.com
Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? - MSN
Market turmoil is tanking biotech M&A and IPOs. Here's the playbook startups will use to survive - Endpoints News
Alnylam at 24th Annual Needham Conference: Strategic Growth in Focus By Investing.com - Investing.com Australia
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Long Term Growth Stock to Buy According to Billionaires? - Insider Monkey
Is Alnylam Pharmaceuticals Gaining or Losing Market Support? - Benzinga
Primary Hyperoxaluria Market to Expand Significantly by 2034, - openPR.com
H.C. Wainwright maintains $500 target on Alnylam stock By Investing.com - Investing.com UK
Alnylam Pharmaceuticals, Inc. (ALNY) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Alnylam and Tekmira Restructure Relationship and Settle All Litigation - AOL.com
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference - BioSpace
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States - Yahoo Finance
Rnai Technology Market Generated Opportunities, Future Scope - openPR.com
RNAi Leader Alnylam Reveals Growth Strategy at Major Healthcare Conference - Stock Titan
Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know - Benzinga
Pfizer's $11.6 billion Biohaven buy could spark more biotech deals - MarketScreener
Sanofi adds to hemophilia arsenal with FDA nod for Qfitlia - BioWorld MedTech
Sanofi, Alnylam win first RNAi approval for hemophilia A and B - PharmaLive
Alnylam Pharmaceuticals' Qfitlia Approved by FDA for Hemophilia A, B Treatment - MarketScreener
Stifel cuts Alnylam stock price target to $300 from $345 By Investing.com - Investing.com UK
FDA Approves Sanofi's Hemophilia Drug - Benzinga
Scotiabank raises Alnylam stock target to $342, maintains rating By Investing.com - Investing.com UK
Stifel raises Alnylam stock price target to $345 on FDA nod - Investing.com India
Redburn-Atlantic sets $353 target on Alnylam stock with Buy rating - Investing.com India
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B - BioSpace
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025 - BioSpace
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Celebrates FDA Approval of Qfitlia Despite 5% Share Price Dip - simplywall.st
Groundbreaking HELIOS-B Trial: AMVUTTRA Proves Major Breakthrough for Heart Disease Patients - Stock Titan
Alnylam’s Qfitlia gets FDA nod for hemophilia treatment By Investing.com - Investing.com South Africa
FDA approves first-of-its-kind RNA drug for hemophilia - BioPharma Dive
Alnylam’s Qfitlia gets FDA nod for hemophilia treatment - Investing.com India
Revolutionary Hemophilia Treatment Achieves 90% Bleed Reduction in FDA Approval - Stock Titan
FDA approves Sanofi’s RNAi drug for hemophilia A and B - Endpoints News
Alnylam CEO's compensation package continues to grow - NBC Boston
Alnylam CEO’s compensation package continues to grow - The Business Journals
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More - Yahoo Finance
Transthyretin Amyloidosis Treatment Market Detailed In New - openPR
Alnylam Pharmaceuticals director David Pyott sells $2.2 million in stock By Investing.com - Investing.com Australia
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? - MSN
Alnylam Pharmaceuticals director David Pyott sells $2.2 million in stock - Investing.com India
Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth in expanding ATTR-CM market - Investing.com India
FDA approves new drug to treat protein buildup in the heart - MSN
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock - Benzinga
FDA OKs Amvuttra To Treat Heart Conditions - The Daily Courier
RBC Capital holds $330 target on Alnylam stock post-Amvuttra approval - Investing.com
Alnylam Pharmaceuticals Stock (ALNY): Innovative Treatment for ATTR Amyloidosis - Value The Markets
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):